For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 4,054,831 | |||
| General and administrative | 5,672,794 | |||
| Legal and professional | 2,189,199 | |||
| Total operating expenses | 11,916,824 | |||
| Net loss from operations | -11,916,824 | |||
| Interest expense-Related Party | 8,730 | |||
| Interest expense-Nonrelated Party | 62,098 | |||
| Interest income | 1,090 | |||
| Change in fair value of derivative liabilities | -74,406 | |||
| Change in fair value of convertible notes | -3,351 | |||
| Gain on settlement of debt | 342,650 | |||
| Total other (expense) income | 195,155 | |||
| Net loss | -11,721,669 | |||
| Basic EPS | -7.16 | |||
| Diluted EPS | -7.16 | |||
| Basic Average Shares | 1,637,926 | |||
| Diluted Average Shares | 1,637,926 | |||
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)